A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECT ON SEIZURES AND BEHAVIORAL SYMPTOMS OF RADIPRODIL IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) OR FOCAL CORTICAL DYSPLASIA (FCD) TYPE II

Registry ID
RAD-GRIN-201
Source registry
HEALTH_CANADA
Status
Ongoing
Study type
INTERVENTIONAL
Sponsor
GRIN THERAPEUTICS, INC
Start date
2025-05-15
Last update
2023-09-27

Conditions

View on source registry